^
Association details:
| Biomarker: | MYC amplification + ALK F1174L |
|---|---|
| Cancer: | Neuroblastoma |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) + Balversa (erdafitinib) (FGFR inhibitor, FGFR4 inhibitor, FGFR1 inhibitor, FGFR2 inhibitor, FGFR3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FGFR2 modulates ALK inhibition response in high-risk neuroblastoma
Published date:
03/15/2023
Excerpt:
In vivo studies using patient-derived xenograft (PDX) models of high-risk NB (MYCN-amplified and ALKF1174L mutant) showed that combinations of either ponatinib or erdafitinib with lorlatinib decreased tumour growth and increased survival compared to PDXs treated with vehicle or either agent alone.
